Myo-inositol Versus Metformin in Patients With Polycystic Ovarian Syndrome to Treat Obesity

Comparison of Myo-inositol Versus Metformin for Treating Obesity in Patients With Polycystic Ovarian Syndrome

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07387679

Enrollment

Registered

2026-02-04

Start date

2024-11-29

Completion date

2025-05-28

Last updated

2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrome

Brief summary

There are considerable gaps in the comparative effectiveness and tolerability of myo-inositol and metformin for treating obesity in patients with polycystic ovarian syndrome (PCOS). The current study aimed to give insights comparing myo-inositol versus metformin for treating obesity in patients with PCOS.

Detailed description

A review of the literature reveals inconsistent outcomes of myo-inositol vs metformin in the treatment of obesity and metabolic disorders in patients with PCOS, with comparable results and myo-inositol frequently demonstrating superior tolerability and reduced gastrointestinal side effects relative to metformin. When treating obesity in women with PCOS, practicing gynecologists would be able to select more appropriate medications by gathering data from local contexts. It will lessen psychological consequences associated with obesity, such as discrimination, stigma, low self-esteem, and poor quality of life.

Interventions

DRUGMyo-inositol

Women were given tablet myo-inositol 1 gm twice a day for 3 months.

DRUGMetformin

Women received metformin 250 mg three times daily for 3 months.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Females aged 18-45 years * Diagnosed case of PCOS for more than 6 months of duration

Exclusion criteria

* Women with hyperprolactinemia or hypothyroidism (on history \& medical record review) * Adrenal hyperplasia or Cushing's syndrome (on history \& medical record review)

Design outcomes

Primary

Measure	Time frame	Description
Reduction in body mass index	3 months	A reduction in the body mass index with respect to baseline was taken as efficacy of the treatment.

Countries

Pakistan

Contacts

PRINCIPAL_INVESTIGATORAyesha Gul

Bahawal Victoria Hospital/Quid-e-Azam Medical College, Bahawalpur

STUDY_DIRECTORShehnaz Anwar, FCPS